Related Experiment Video
Updated: Jun 18, 2025
06:51
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
5.3K
Injectable chitosan hydrogel effectively controls lesion growth in a venous malformation murine model.
Ha-Long Nguyen1, Ricardo Holderbaum Do Amaral2, Sophie Lerouge3
1Human Molecular Genetics, de Duve Institute, University of Louvain, B-1200 Brussels, Belgium.
Diagnostic and Interventional Imaging
|August 2, 2024
Summary
Chitosan hydrogel combined with sodium tetradecyl sulfate effectively controlled venous malformation growth in mice, showing promise against the standard treatment. This novel approach offers a potentially superior option for treating these vascular anomalies.
Area of Science:
- Vascular biology
- Biomaterials science
- Sclerotherapy
Background:
- Venous malformations (VMs) are complex vascular anomalies requiring effective treatment.
- Current treatments like sodium tetradecyl sulfate (STS) foam have limitations.
- Novel therapeutic strategies are needed to improve VM management.
Purpose of the Study:
- To evaluate the safety and efficacy of intralesional chitosan hydrogel (CH) combined with STS for sclerosing and embolizing VMs.
- To compare CH-STS formulations against 3% STS foam and placebo in a mouse model.
Main Methods:
- Subcutaneous VMs were induced in athymic mice.
- Established VM lesions were treated with saline, 3% STS foam, CH, 1% STS-CH, or 3% STS-CH.
- Lesion size was monitored, and histological analysis assessed vessel size and chitosan distribution.
Main Results:
- Both CH formulations (1% and 3% STS-CH) effectively controlled VM growth compared to untreated and 3% STS-foam groups.
- CH formulations resulted in smaller vessel sizes than untreated and saline groups.
- The 1% STS-CH group showed smaller vascular channels than the 3% STS-foam group, despite some treatment-related skin ulcerations.
Conclusions:
- Chitosan hydrogel formulations demonstrate significant potential in controlling VM growth.
- CH-STS therapies may offer superior outcomes compared to the current gold standard, STS-foam, for specific variables.
- Further research into CH-based sclerotherapy for VMs is warranted.
